Joint Corp Cuts 2026 Sales Guidance, Posts $1.5M Q3 Continuing-Operations Profit, Adds $5M Buyback
JYNT is trading near its 52-week low of $6.79 (8.5% above the low).
Summary
Joint Corp cut its 2026 system-wide sales guidance to $508M-$512M from $519M-$552M on weak consumer spending, while Q3 continuing-operations net income rose to $1.5M and the board added $5.0M to the buyback; on October 1, 2026 it reacquired Texas regional developer rights for 141 franchised clinics for $8.0M cash plus up to $2.0M in contingent payments.
Updated with a GlobeNewswire report · What changed
Updates
· GlobeNewswire — Joint Corp reacquired Texas regional developer rights for 141 franchised clinics on October 1, 2026, for $8.0M cash plus up to $2.0M in contingent payments.
Key Events · Earnings and Guidance · JYNT
-
New · · GlobeNewswire
Texas Developer Rights Reacquired for $8.0M
On October 1, 2026, the company reacquired the Texas regional developer rights for 141 franchised clinics for $8.0M in cash plus up to $2.0M in contingent payments.
-
2026 Sales Guidance Cut
Full-year system-wide sales guidance was lowered to $508M-$512M from $519M-$552M, and comp sales to (3.5)%-(2.5)% from (3)% to 3%, citing continued macroeconomic pressure on consumer spending.
-
Q3 Continuing-Operations Profit Up
Revenue rose 1% to $13.6M; net income from continuing operations was $1.5M versus $290,000 a year ago, and Adjusted EBITDA from continuing operations was $2.3M versus $1.4M.
-
Consolidated Result Turns Negative
A $1.6M loss from discontinued operations drove a consolidated net loss of $117,000, compared with $855,000 of net income in Q3 2025; consolidated Adjusted EBITDA was flat at $3.3M.
-
Buyback Raised by $5.0M
The board authorized an additional $5.0M on November 3, 2026 after the prior $12M authorization was exhausted; Q3 repurchases totaled ~461,000 shares for ~$3.8M at an average of $8.30 per share.
Analysis · JYNT · Real Estate & Construction
The guidance cut is the headline: full-year system-wide sales are now $508M-$512M versus the prior $519M-$552M, and comp sales are now expected at (3.5)% to (2.5)% versus (3)% to 3%. That is a meaningful reduction at the top line, driven by weaker consumer spending and fewer new patients. The offset is that the refranchised, capital-light model is producing better profitability from continuing operations — net income of $1.5M versus $290,000 a year ago and Adjusted EBITDA of $2.3M versus $1.4M — while consolidated Adjusted EBITDA guidance of $12.5M-$13.5M was left unchanged. The board also added $5.0M to the buyback after the prior $12M authorization was fully used, which supports the stock but does not change the softer demand picture. Separately, on October 1, 2026 the company reacquired the Texas regional developer rights for 141 franchised clinics for $8.0M in cash plus up to $2.0M in contingent payments.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JYNT was trading at $7.37 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $104.2M. The 52-week trading range was $6.79 to $10.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.